We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

38 hedge funds and large institutions have $18.7M invested in Lumos Pharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 37 → 38 (+1)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

31% less capital invested

Capital invested by funds: $27.3M → $18.7M (-$8.53M)

Holders
38
Holders Change
+1
Holders Change %
+2.7%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
9
Closed
5
Calls
$30K
Puts
–
Net Calls
+$30K
Net Calls Change
+$30K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$2.99M
2
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$87.1K
3
PAM
PVG Asset Management
Colorado
+$85.5K
4
UBS Group
UBS Group
Switzerland
+$43K
5
Osaic Holdings
Osaic Holdings
Arizona
+$11.4K

Top Sellers

Rank Fund Capital Flow
1
LPC
Lion Point Capital
New York
-$2.99M
2
NMC
NEA Management Company
Maryland
-$1.26M
3
Millennium Management
Millennium Management
New York
-$146K
4
Citadel Advisors
Citadel Advisors
Florida
-$113K
5
Renaissance Technologies
Renaissance Technologies
New York
-$78.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Blackstone Inc
1
Blackstone Inc
New York
$3.24M – – –
NMC
2
NEA Management Company
Maryland
$2.61M -$1.26M -149,747 -28%
Goldman Sachs
3
Goldman Sachs
New York
$2.47M +$2.99M +355,990 New
Wells Fargo
4
Wells Fargo
California
$2.19M -$10.2K -1,212 -0.4%
Renaissance Technologies
5
Renaissance Technologies
New York
$1.92M -$78.1K -9,300 -3%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.65M -$7.74K -921 -0.4%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$1.11M – – –
JG
8
Jefferies Group
New York
$836K – – –
BlackRock
9
BlackRock
New York
$427K +$5.44K +647 +1%
LPC
10
Lion Point Capital
New York
$354K -$2.99M -355,987 -87%
BCM
11
Bridgeway Capital Management
Texas
$331K – – –
MA
12
Minerva Advisors
Pennsylvania
$236K – – –
Connor, Clark & Lunn Investment Management (CC&L)
13
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$232K – – –
IFG
14
Investors Financial Group
Minnesota
$212K -$33.6K -4,000 -12%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$196K -$67 -8 -0%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$144K -$1.86K -222 -1%
MAM
17
Marquette Asset Management
Minnesota
$92K +$681 +81 +0.6%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$83K – – –
WAOI
19
Wealth Advisors of Iowa
Iowa
$81K -$513 -61 -0.5%
State Street
20
State Street
Massachusetts
$78K – – –
Envestnet Asset Management
21
Envestnet Asset Management
Illinois
$72K +$87.1K +10,368 New
PAM
22
PVG Asset Management
Colorado
$70.5K +$85.5K +10,175 New
UBS Group
23
UBS Group
Switzerland
$39K +$43K +5,121 +1,083%
Osaic Holdings
24
Osaic Holdings
Arizona
$20K +$11.4K +1,360 +82%
APA
25
American Portfolios Advisors
New York
$8.66K +$10.5K +1,250 New
1
2

LUMO Hedge Fund Activity: Q4 2021 in Review

38 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2021, worth a combined $18.7M — down 31% from $27.3M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new LUMO positions and 5 closed out — a net gain of 1 holder — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $2.99M. The largest seller was Lion Point Capital, cutting an estimated $2.99M.

  • 38 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2021, up from 37 in Q3 2021.
  • Funds reported $18.7M of Lumos Pharma, Inc. Common Stock stock for Q4 2021, down 31% quarter-over-quarter.
  • 6 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2021 and 5 closed out, a net change of +1 holder.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2021 was Goldman Sachs, an estimated $2.99M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2021 was Lion Point Capital, an estimated $2.99M sold.

Based on aggregated 13F filings for Q4 2021.